Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533946 · ClinicalTrials.gov registry record · Phase 2
Rucaparib in Nonmetastatic prOstAte With BRCAness
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03533946: Clinical Trial Phase 2 study, sponsored by University of Utah.
NCT03533946 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03533946, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a single arm, open label, phase II trial to assess efficacy of rucaparib.
Primary Outcome
The levels of PSA were monitored monthly for comparison to baseline levels until the time of PSA progression, or 2 years after study treatment discontinuation, or study termination, as defined by Prostate Cancer Working Group 3 (PCWG3) criteria. PCWG3 criteria for PSA progression is a rise over baseline of \>= 25% and an absolute rise of \>= 2 ng/mL. Reported as median number of months from baseline to PSA progression.
Interventions
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2023-01-12 |
| Phase | Phase 2 |
Why NCT03533946 stopped before completion
NCT03533946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Rucaparib is the first listed.
NCT03533946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03533946 about?
NCT03533946 is a clinical study titled "Rucaparib in Nonmetastatic prOstAte With BRCAness". This is a single arm, open label, phase II trial to assess efficacy of rucaparib.
What is the current status of trial NCT03533946?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-05-20. Estimated completion is 2023-01-12.
What interventions are being tested in trial NCT03533946?
The interventions under investigation include: Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03533946?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03533946's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI